Abstract 543P
Background
Ovarian cancer (OC) is the second most common gynecologic malignancy and the leading cause of gynecologic cancer death. Women with recurrence of OC have a poor prognosis, yet there is a subset of patients who are long term survivors (LTS). We sought to characterize prognostic measures associated with short and long-term survivorship of women with advanced OC.
Methods
A retrospective descriptive analysis of 966 patients diagnosed with epithelial OC (EOC) and treated at a single institution between 2002-2020. Patient characteristics of women who survived less than 2 years were compared to three cohorts of LTS, women who lived more than 5, 7 and 10 years, respectively. We assessed the contribution of age and stage, histology, BRCA carrier status, interval or primary debulking, optimal debulking, upon oncological outcomes of women.
Results
Among 966 women with EOC, a large proportion of women diagnosed with FIGO stage III-IV disease were LTS, with 30.9%, 16.93% and 7.8% of women who survived over 5, 7 and 10 years, respectively, while 13.64% survived less than 24 months. LTS were characterized as younger, diagnosed at an earlier stage, optimally debulked (R0), BRCA mutation carriers, and displayed a platinum sensitive disease (P<.0001). Histology, CA125 at diagnosis and debulking approach did not influence the likelihood of long-term survivorship. Bevacizumab therapy did not increase the likelihood of long-term survivorship, while PARP inhibitors was a significantly integrated into the treatment regimen of LTS. A greater proportion of LTS received weekly treatment scheduling in comparison to the standard 3-weekly regimen of chemotherapy (P<.01). Interestingly, a comparable proportion of women achieved complete cytoreduction R0, R1 and R2 among those treated with primary and interval debulking (P=.1713). Patients with R2 cytoreduction were twice as likely to die of their disease in comparison to patients with R0 resection (H.R. 2.303, P<.0001).
Conclusions
This work reflects real-life data of EOC survivorship, commonly considered a disease with dismal outcomes. Our work demonstrated that the EOC LTS are a well characterized population diagnosed at a younger age, lower stage and harboring BRCA mutations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.